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Percutaneous Radiofrequency Ablation for
the Hepatocellular Carcinoma Abutting
the Diaphragm: Assessment of Safety and
Therapeutic Efficacy
Objective: To assess the safety and therapeutic efficacy of a percutaneous
radiofrequency (RF) ablation for the hepatocellular carcinoma (HCC) abutting the
diaphragm.
Materials and Methods: We retrospectively assessed 80 patients who under-
went a percutaneous RF ablation for a single nodular (< 4 cm) HCC over the last
four years. Each patient underwent an ultrasound-guided RF ablation using inter-
nally cooled electrodes for the first-line treatment. We divided patients into two
subgroups based on whether the index tumor was abutting (less than 5 mm) the
diaphragm or not: group A (abutting; n = 31) versus group B (non-abutting; n =
49). We compared the two subgroups for complications and therapeutic efficacy
using image and the review of medical records. The statistical assessment
included an independent t-test, Fisher’s exact test, and chi-square test. 
Results: The assessment of the diaphragmatic swelling at CT immediately fol-
lowing the procedure was more severe in group A than group B (mean thickness
change:1.44 vs. 0.46 mm, p = 0.00). Further, right shoulder pain was more com-
mon in group A than B (p = 0.01). Although minor complications (hemothorax 1
case, pleural effusion 1 case) were noted only in group A, no major thoracic com-
plication occurred in either group. The technical success rate was lower in group
A than group B (84% vs. 98%, p = 0.03). As well, the primary and secondary
technique effectiveness rates in group A and group B were 90% versus 98% (p =
0.29) and 79% versus 91% (p = 0.25), respectively. The local tumor progression
rate was higher in group A than in group B (29% vs. 6%, p = 0.02).
Conclusion: We found that the percutaneous RF ablation for the HCC abutting
the diaphragm is a safe procedure without major complications. However, it is
less effective with regard to technical success and local tumor control.
adiofrequency (RF) ablation is one of the most effective techniques for
local treatment of hepatocellular carcinoma (HCC) and hepatic metastasis
(1, 2). Recent clinical studies on the RF ablation of hepatic tumors have
reported low rates of morbidity and favorable local tumor control rates. Although the
RF ablation has been accepted as a safe procedure, potential complications can arise
including bleeding, infection, and collateral thermal injury (3-6). 
Unintended thermal injury may occur in the structures close to the tumor ablation
zone, including the gastrointestinal region, biliary tracts, and the diaphragm. If an
index tumor abuts one of these organs, the operator must consider the balance
between two conflicting factors: safe ablation versus complete ablation (7-10). If the
index tumor is located in the hepatic dome, the tumor frequently abuts the diaphragm
and has a limited sonic window due to overlapped lung or ribs. Therefore, due to these
Tae Wook Kang, MD
Hyunchul Rhim, MD
Eun Young Kim, MD
Young-sun Kim, MD
Dongil Choi, MD
Won Jae Lee, MD
Hyo K. Lim, MD
Index terms:
Hepatocellular carcinoma
Diaphragm
Radiofrequency ablation
Ultrasonography
Computed tomography (CT)
DOI:10.3348/kjr.2009.10.1.34
Korean J Radiol 2009;10:34-42
Received July 5, 2008; accepted 
after revision August 12, 2008.
All authors: Department of Radiology and
Center for Imaging Science, Samsung
Medical Center, Sungkyunkwan
University School of Medicine, Seoul 
135-710, Korea
Address reprint requests to:
Hyunchul Rhim, MD, Department of
Radiology and Center for Imaging
Science, Samsung Medical Center,
Sungkyunkwan University School of
Medicine, 50 Irwon-dong, Gangnam-gu,
Seoul 135-710, Korea.
Tel. (822) 3410-2507
Fax. (822) 3410-2559
e-mail: rhimhc@skku.edu
Rdifficulties the percutaneous ablation of hepatic tumors
abutting the diaphragm may result in poor clinical
outcomes with high morbidity and low local tumor control
(11, 12). 
To our knowledge, several reports of thoracic complica-
tions such as diaphragmatic perforation, right shoulder
pain, pleural effusion, and other problems following an RF
ablation of subcapsular tumors abutting the diaphragm
have been reported (5, 9, 10, 13-16, 21-23). However, no
comparative studies have been performed using a control
group to focus on the occurrence of thermal injury of the
diaphragm. The purpose of this study was to retrospec-
tively evaluate the safety (by focusing on the occurrence of
thermal injury of the diaphragm) and the therapeutic
efficacy of the percutaneous RF ablation for the HCC
abutting the diaphragm, compared to a non-abutting
control group.
MATERIALS AND METHODS
Patient Selection
Written informed consent was obtained from every
patient prior to treatment.  From August 2000 to March
2006, 627 patients with HCC were treated with 944 RF
ablation procedures at our institution. The 627 patients
included 469 men and 158 women ranging in age from 20
to 88 years (mean: 58.52 years). Among them, 80 patients
were included in the study group. All patients included in
the study met the following criteria for a percutaneous RF
ablation: a single nodular HCC with a tumor size not
exceeding 4 cm in maximum diameter, tumors located in
liver segments 4, 7, and 8 above the portal bifurcation, and
at least 4 follow-ups (immediately after, 1, 4,  and 7
months). Other conditions for inclusion in this study
include: no cases of portal vein thrombosis or extrahepatic
metastases, use of an internally cooled electrode system for
the procedure, a Child-Pugh classification of A or B for
liver cirrhosis, normal coagulation data, no prior treatment
for HCC, tumor visible on planning sonography, and
tumor accessibility by the percutaneous approach. 
For the diagnosis of HCC, pre-procedural imaging
studies using combined sonography and CT or sonography,
CT, and enhanced MRI were performed on all patients. All
tumors were considered to be HCCs based on imaging
findings (newly developed tumor on a follow-up sonogra-
phy in patients with chronic liver disease and characteristic
enhancement pattern on contrast-enhanced multiphase
helical CT or dynamic contrast-enhanced MRI). Among
them, 18 patients had elevated serum tumor markers ( -
fetoprotein > 200 ng/mL) and another 13 patients had a
confirmed diagnosis via a percutaneous needle biopsy. 
We defined patients with tumors abutting the diaphragm
when tumors were near the diaphragm (< 5 mm) on axial
CT scan imaging. All tumors in this study were located in
liver segment 4, 7, and 8 for an easy and accurate assess-
ment of diaphragm thickness. Eighty patients were divided
into two groups depending on whether the tumor was
abutting the diaphragm or not: group A (abutting: n = 31),
group B (non-abutting; n = 49). No statistically significant
differences in the baseline characteristics of the group A
and group B were found, except the distance from the
diaphragm. The distance from diaphragm was defined as
the nearest distance between tumor and diaphragm (Table
1). 
Radiofrequency Ablation Procedure
Descriptions of the RF ablation procedure in this study
follow the proposed standardization of terminology and
reporting criteria (17). Vital signs and pain were continu-
ously monitored during the procedure. All procedures
were performed under conscious sedation using 50 mg of
pethidine hydrochloride, intravenously (Samsung
Pharmaceutical; Korea). Next, local anesthesia was
provided by injecting an anesthetic (lidocaine; Kwang
Myung Pharmaceutical; Korea) from the skin to the liver
capsule along the planed RF electrode path. To avoid
puncture of the tumor along the exposed liver surface,
indirect access through the intervening non-tumorous liver
parenchyma was used all cases. The RF ablation was
performed under real-time US guidance (HDI 3000 or
5000, ATL) by one of three experienced radiologists (9,
10, 7 years experience with local ablation therapy, respec-
tively). We used an internally cooled electrode system
(Cool-tip; Valleylab; Boulder, CO). This system includes an
electrode with an internally cooled tip (by chilled saline).
The device was equipped with a 200-W generator and uses
either a single 17-gauge straight electrode or a cluster
electrode consisting of three electrodes mounted on a
common handle in a triangular fashion. The algorithm of
energy deposition followed the manufacturer’s
recommended protocol for the device. The therapeutic
strategy of the radiofrequency ablation consisted of includ-
ing a peripheral margin of at least 0.5 cm of normal hepatic
parenchyma surrounding the tumor and the entire tumor
itself as soon as possible. We cauterized the electrode path
during retraction of the electrode to minimize bleeding
after ablation and to avoid track seeding. We performed
single or multiple overlapping ablations (mean: 1.21
ablations / tumor) to destroy the entire tumor (including
the ablative margin). The mean duration of a complete RF
ablation during the initial session was 16.32 min (8-36
min) in group A and 13.10 min (8-20 minutes) in group B.
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RF ablation procedure. After the procedure, a physician
evaluated each patient for right shoulder pain for the
approximate location and duration in a ward. 
Follow-up Imaging
For the initial evaluation of procedure-related complica-
tions and therapeutic response, all patients immediately
contrast-enhanced a three phase CT within two hours after
the RF ablations. If residual tumor or unablated therapeu-
tic margin was detected, additional RF ablation was
repeated for a second session on the following day. We
used a helical scanner (HiSpeed Advantage, GE
Healthcare, Milwaukee, WI) with a 5-mm slice thickness as
in the pre-procedural imaging study. A total of 120 mL of
nonionic contrast material (Ultravist 300 [iopromide, 300
mg I/mL], Schering, Berlin, Germany) was administered at
a rate of 3 mL/sec with an automatic power injector. The
scan images were acquired at pre-injection, 30, 70, and
180 sec after IV contrast material injection.
Correspondingly, these represent the non-enhanced,
hepatic arterial, portal venous, and equilibrium phases,
respectively. All scans were obtained by using a 0.625 mm
collimation beam at 200 mA and 120 kVp.
To evaluate the response to each of the RF ablations,
scheduled follow-up contrast-enhanced CT scans, with the
same parameters as the pre and immediately after scanning
were performed on the day following treatment to assess
the outcome at 1, 4, and 7 months, as well as one year or
more after treatment. All follow-up CT scans were
evaluated by the consensus of two abdominal radiologists.
Assessment of Safety and Therapeutic Efficacy
For the assessment of safety, we evaluated whether any
thoracic complications occurred; including collateral
thermal injury at the diaphragm adjacent to the RF
ablation zone. In addition, we assessed the change in the
diaphragm thickness at the initial and follow-up CT scans.
Diaphragmatic thickness was defined as the thickest
measurable portion of the diaphragm when that portion
abutted the ablation zone on axial CT scanning (immedi-
ately after an RF ablation). Two radiologists measured the
diaphragm thickness independently using a magnification
view of the picture archiving and communication system
(GE PACS, GE Healthcare). The results of each radiologist
were averaged. The measurements of the initial and
follow-up CT scans were compared at the same level as
soon as possible. Each case was adjusted for CT window
level optimization to delineate the diaphragm. One radiol-
ogist reviewed the electronic medical records of all patients
for levels of pain medication as well as the presence and
duration of persistent right shoulder pain after the RF
ablation. We excluded transient and tolerable right
shoulder pain during the RF ablation procedure without
the administration of pain medication.
The description of complications and therapeutic efficacy
in this study follow the proposed standardization of
terminology and reporting criteria (17). Major complica-
tions are described as conditions that may lead to death if
untreated, as well as conditions resulting in substantial
morbidity and disability or a lengthened hospital stay. All
other complications were considered to be of minor
complications.
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Table 1. Comparison of Baseline Characteristics of Patients between Group A and Group B 
Characteristic
Group 
P value
A (n = 31) B (n = 49)
Mean age (yr)  59.25  9.800 60.00  10.46 0.32
Sex (M:F) 20:11 37:12 0.75
Mean follow-up period (month) 
� 18.48  12.51 17.71  9.770 0.76
Cause 
HBV 17 35 0.24
HCV 10  12
NBNC 04 02
Child class
A   25 40 0.91
B 06 09
Mean tumor size (cm) 
� 2.39  0.69 2.13  0.58 0.06
Mean  -FP (ng/mL) 
� 087.02  170.32 088.11  779.09 0.98
Mean distance from diaphragm (cm) 
� 0.21  0.25 2.06  1.12 < 0.01
Note.─ Group A = abutting diaphragm, Group B = non-abutting diaphragm, HBV = hepatitis B virus, HCV = hepatitis C virus, NBNC = non-hepatitis B virus 
and non-hepatitis C virus. 
� Data are expressed as means  standard deviations. To assess the therapeutic efficacy, we evaluated the
technical success rate, primary technique effectiveness rate,
secondary technique effectiveness rate, and local tumor
progression rate. Technical success was defined by tumor
treatment according to protocol and the achievement of
complete tumor ablation after one session immediate as
well as after a follow-up CT scan of the first RF ablation
session. The primary technique effectiveness rate is defined
as the percentage of tumors that were successfully
eradicated at the one month follow-up CT. Secondary
technique effectiveness rate was determined by a 1-year or
later follow-up CT and included cases that underwent
successful repeated percutaneous RF ablations following
the identification of local tumor progression. Local tumor
progression was diagnosed with the identification of
untreated disease foci in tumors that were previously
considered to be completely ablated. These tumors had to
be considered completely ablated by the definition used
for primary effectiveness. The mean follow-up period was
18 months (7-67 mos). We found was no statistically
significant differences between the both groups.
Statistical Analysis 
A comparison between the two groups using indepen-
dent t-test for continuous variables was carried out. A
Fisher’s exact test and chi-square test were used to analyze
differences in the complication rate and therapeutic
efficacy. All statistical tests were two-tailed and a p < 0.05
was considered statistically significant. All statistical
analyses were performed with SPSS 10.0 (SPSS Inc.,
Chicago, IL). 
RESULTS
Safety
Collateral Thermal Injury of the Diaphragm
The mean increase in diaphragmatic thickness between
pre and immediately after RF ablations on CT scans were
1.44 mm for group A and 0.46 mm for group B. These
differences were statistically significant (p < 0.01). The
mean diaphragm thickness was measured for its maximum
value for the immediate follow-up CT for group A (2.84
mm) and group B (2.00 mm). The sequential diaphragmatic
thickness change was observed to determine the decrease
in diameter with time in both groups (Figs. 1, 2).
Mortality and Major Complications
There were no deaths related to the RF ablation
procedures. Six patients died during the follow-up period.
The causes of the deaths were aggravation of underlying
liver cirrhosis in five patients and brain infarction in one
patient.  No major complications leading to substantial
morbidity and disability, or extension of the hospital stay
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Fig. 1. Comparison of diaphragm thickness between abutting
group A and non-abutting group B.
Graph shows changes in diaphragmatic thickness in two groups
after radiofrequency ablation. Mean increase in diaphragmatic
thickness between pre- and immediately after radiofrequency
ablation on CT scanning was 1.44 mm for abutting group A and
0.46 mm for non-abutting group B. This difference was statisti-
cally significant (p < 0.01). Diaphragmatic thickness sponta-
neously decreased over time.
Fig. 2. 76-year-old man with hepatocel-
lular carcinoma showing diaphragm
swelling and enhancement.
A. Portal phase CT scan obtained prior
to radiofrequency ablation shows
enhancing nodule (black arrow) in
segment VIII. White line = diameter of
diaphragm thickness.
B. Portal phase CT scan obtained
immediately after radiofrequency
ablation shows ablation zone (A) with
minimal amount of fluid collection.
Swelling and enhancement of
diaphragm is noted as thermal injury for
abutting ablation zone (white arrow).
White line = diameter of diaphragm
thickness. ABwas noted in either group (Table 2).
Minor Complications
In the group A, eight patients had right shoulder pain
after the RF ablation compared with two patients in the
group B. Only two of these patients needed analgesics to
control the pain in group A. The mean duration of right
shoulder pain after RF ablation was 1.75 days for group A
(0-2 days), and 1 day for group B (0-1 day). 
Other minor complications for group A included one
patient with asymptomatic pleural effusion and another
with a small sized hemothorax after the ablation
procedure. For the hemothorax case, the patient had two
therapeutic sessions due to the detection of residual tumor
for the immediate follow-up CT after the first session (Fig.
3). Neither of these two patients had respiratory symptoms
and received only conservative treatment without transfu-
sion or pleural tapping. For group A, seven patients had
abnormal parenchymal densities detected in the right
lower lobe for the CT immediately after the RF ablation.
However, these patients had no respiratory symptoms. In
the follow-up serial CT scans, the abnormal parenchymal
densities spontaneously resolved without specific
treatment (Fig. 4). We considered these imaging findings
transient lung injury. By contrast, there were no thoracic
complications in the group B (Table 2). 
Therapeutic Efficacy
Technical Success
The technical success rate (84%, 26/31) in group A was
Kang et al.
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Fig. 3. 67-year-old man with hepatocellular carcinoma showing incomplete ablation and hemothorax. 
A. Arterial phase CT scan obtained immediately after first session of radiofrequency ablation shows residual enhancing lesion (white
arrow) at central portion of index tumor.
B. Second radiofrequency ablation session of residual tumor was performed on next day. However, persistent enhancing viable portion
at ablation margin is noted immediately after radiofrequency ablation (white arrow). Hemothorax (H) at right lung is associated with
diaphragmatic thermal injury. At that time, patient’s vital signs were stable and resulted in use of conservative treatments only.
AB
Table 2. Thoracic Complications following Percutaneous Radiofrequency Ablation of Hepatocellular Carcinoma between
Group A and Group B
Thoracic Complications
Group 
P value
A (n = 31) B (n = 49)
Major complication 0 0
Minor complications and side effects
Hemothorax  1 (3%)0 0 0.39
Pneumothorax 0 0
Pleural effusion 1 (3%)0 0 0.39
Right shoulder pain 8 (26%) 2 (4%) 0.01
Transient lung injury 7 (23%) 0 < 0.01
Note.─ Group A = abutting diaphragm, Group B = non-abutting diaphragm 
*P values were calculated by using Fisher’s exact test.significantly lower than that group B (98%, 48/49) for the
initial session (p = 0.03) (Table 3). 
Primary and secondary technique rate of efficacy. At the
one month follow-up CT, the primary technique rate of
efficacy rate was 90% (28/31) for group A, compared to
98% (48/49) for group B (p = 0.29). As mentioned above,
five patients in group A failed to undergo a complete
ablation of the tumor during the first session. These
patients required additional tumor ablations in additional
sessions. However three patients in group A continued to
have viable portions of the tumor identified at the immedi-
ate follow-up CT after additional sessions, which was due
to the difficulty of targeting a tumor adjacent to the
diaphragm. These cases were treated by transarterial
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Table 3. Comparison of Therapeutic Efficacy of Percutaneous Radiofrequency Ablation for Removal for Hepatocellular
Carcinoma between Group A and Group B
Therapeutic Efficacy (%)
Group 
P value*
A (n = 31) B (n = 49)
Technical success rate 84 (26/31) 98 (48/49) 0.03
Primary technique effectiveness rate 90 (28/31) 98 (48/49) 0.29
Secondary technique effectiveness rate 79 (19/24) 91 (32/35) 0.25
Local tumor progression rate 29 (8/28)0 6 (3/48) 0.02
Note.─Group A = abutting diaphragm, Group B = non-abutting the diaphragm   
*P values were calculated by using Fisher’s exact test and chi-square test.
AB
Fig. 4. 69-year-old man with hepatocellular carcinoma showing transient
lung injury.
A. Arterial phase CT scan obtained prior to radiofrequency ablation shows
enhancing nodule abutting diaphragm in liver segment VII (black arrow).
B. In lung window setting obtained immediately after radiofrequency ablation
indicated abnormal parenchymal density at right lower lobe (white arrow).
Patient was asymptomatic at time. 
C. Without any specific treatment, lesion resolved at one month follow-up CT
scan.
Cchemoembolization (TACE). One patient in the group B
had an enhancing lesion adjacent to the ablated margin
detected at the 1-month follow-up CT and was also treated
by TACE.
Among the 80 study patients, the secondary technique
effectiveness rates was evaluated in 59 patients who had a
one year or more follow-up with CT. The secondary
technique effectiveness rates was 79% (19/24) in group A,
compared to 91% (32/35) in the group B (p = 0.25) (Fig. 5,
Table 3). 
Local Tumor Progression
On the follow-up CT, local tumor progression was
observed in 29% (8/28) at the ablation margin in Group A
and 6% (3/48) in group B. This difference was significant
(p = 0.02) (Table 3). On the other hand, the mean
detection time for local tumor progression on follow-up CT
was 9.5 months for group A and 10.25 months for group
B. This difference was not statistically significant (p =
0.09). 
DISCUSSION
The diaphragm is innervated by both phrenic nerves
arising from the nerve roots (C3, 4, and 5), which
represent the same dermatome as in shoulder skin. Thus,
diaphragmatic irritation is referred to the shoulder and
irritation of the diaphragm can cause right shoulder pain
(18). Further, thermal injury to tissue causes increase in
tissue volume and water content and has been
demonstrated experimentally (19, 20). Hence, we consid-
ered an increase in the diaphragmatic thickness and right
shoulder pain (referred pain) as the representative indica-
tors of diaphragmatic thermal injury.   
Our study demonstrated that changes in diaphragmatic
thickness after an RF ablation for CT images in the
abutting group were significantly greater than the non-
abutting group. Also, the mean distance from the
diaphragm in the non-abutting group was greater than the
abutting group (2.06 vs. 0.21 cm, p < 0.01). Moreover, the
mean total RF ablation time during the first session, was
longer in the abutting group than the non-abutting group
(16.32 vs. 13.10 min, p = 0.02). Therefore, the distance
between the index tumor and diaphragm as well as the
ablation time could be an important factor for the risk of
collateral thermal injury of the diaphragm. 
Although the degree of thermal injury to the diaphragm
and basal lungs at the immediate CT scan was more severe
in the abutting group, these changes spontaneously
improved without substantial mortality or significant
morbidity in either group. Thus, we suggest that hepatic
tumors abutting the diaphragm can safely be treated by a
percutaneous RF ablation without significant morbidity. In
comparison to the recent study by Head et al. (21), our
data have show a lower incidence, duration of right
shoulder pain, and local tumor recurrence rate. These
differences may be due to the definition of “abutting the
diaphragm” and “tumor size” because their study included
larger sized tumors, which were on average at a closer
proximity to the diaphragm.
Our study demonstrated that the percutaneous RF
ablation for HCC was more effective in the non-abutting
group compared to abutting group in terms of technical
success and local tumor progression. In three of five
patients in the abutting group with technical failure after
the first session of ablation, complete ablation was not
achieved; even after a second session of ablation on the
following day. The main reason for the technical failure in
the abutting group was attributed to the difficulty in target-
ing the tumor by the RF electrode. This is a well-known
problem in US-guided interventions of hepatic focal lesions
in the hepatic dome. If the index tumor is located in the
hepatic dome, the boundary of the tumor is usually only
partially visible due to overlap of the lungs, even at a deep
inspiration state. Another reason for technical failure in
our series of patients was the use of the straight type RF
Kang et al.
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Fig. 5. Flow diagram showing primary and secondary technique
effectiveness rates in this study. At one month follow-up CT,
primary technique effectiveness rates was 90% (28/31) in group
A, compared to 98% (48/49) in group B (p = 0.29). Among 80
patients, secondary technique effectiveness rates was evaluated
in 59 patients who had one year or more of follow-up with CT.
Secondary technique effectiveness rates was 79% (19/24) in
group A, compared to 91% (32/35) in group B (p = 0.25). Both
primary and secondary technique effectiveness rates showed no
statistically measurable difference. Group A = abutting
diaphragm, group B = non-abutting diaphragmelectrodes. These can be dislocated by expiration during
the ablation, especially if the index tumor is targeted
during deep inspiration. 
We found that the local tumor progression rate was
significantly higher in the abutting group compared to the
non-abutting group. The reasons for these differences may
be similar to those for the differences outlined in the
technical success rate. The most probable explanation for
the difference in local tumor progression rate is the accessi-
bility of the tumor for the RF ablation. The operator’s
concern of thermal injury to the adjacent diaphragm may
lead to incomplete (suboptimal) ablation because it is very
difficult to monitor the RF ablation zone and the
diaphragm in the subphrenic area with a poor sonic
window and an ill-defined hyperechoic zone during the
ablation.
Recently, Teratani et al. (16) reported the clinical results
of the use of RF ablations for HCC at high-risk locations.
They reported that HCC nodules adjacent to a large vessel
or extrahepatic organ were treated with RF ablations
without compromising safety or therapeutic efficacy. The
reason for the differences with our study is that they
routinely used artificial pleural effusion for cases with
tumors abutting the diaphragm or artificial ascites in cases
when tumors abutted the gastrointestinal tract. In addition,
our results for the local tumor progression rate were
contrary to recent studies using a control group by Kim et
al. (13), Cho et al. (22), and Sartori et al. (23). Kim et al.
reported no significant difference in the local tumor
progression rate between subcapsular HCCs and nonsub-
capsular HCCs. However, their study groups showed that
they included cases such that significantly larger tumor
sizes were included in the subcapsular HCCs group
compared to the nonsubcapsular HCCs group. The Cho et
al. study population included patients with multiple HCCs.
Moreover, their total study population was relatively low.
Further, Satorini et al. included study patients with hepatic
metastatic lesions; and our definition of a subcapsular
tumor was closer to that of a tumor. These differences may
account for the differences in study outcome. Their studies
reported better therapeutic efficacy including local tumor
progression in subcapsular HCCs compared with our
study. 
Currently, the only way to achieve safe and complete
ablation with an ablative margin, is to separate the RF
ablation zone from organs in danger of being injured. To
separate between the index tumor and adjacent organs,
several studies have evaluated the use of artificial materials
between the index tumor and abutting organs for the
percutaneous RF ablation. Various methods such as the
injection of artificial ascites, pleural effusion, and intra-
abdominal carbon dioxide insufflation are reported to
minimize diaphragmatic thermal injury during percuta-
neous RF ablation (15, 24-30). These studies are based on
the hypothesis that the RF ablation of tumors adjacent to
the organs poses a substantial risk of thermal injury. The
results of our comparative study may support the previous
studies which use artificial ascites and pleural effusion
during an RF ablation for lesions that abut the diaphragm
(with regard to therapeutic efficacy). Further, these
additional techniques may be supportive in preventing
technical failure and may also reduce the rate of local
tumor progression. 
Our study did have certain limitations. First, we
evaluated the thermal injury of the diaphragm by indirect
methods (using diaphragm thickness and right shoulder
pain) because we could not assess the pathologic grading of
the thermal injury [as in the animal study by Raman et al.
(28, 29)]. We also had to measure the change in diaphrag-
matic thickness on CT as a quantitative assessment of the
degree of diaphragmatic thermal injury. In addition, we
performed axial CT scan images without multi-planar
reconstruction images (31). Further the respiratory
movement during CT scanning influences the evaluation of
diaphragm thickness. As well, we only reviewed for the
presence of right shoulder pain without a validated pain
assessment tool (such as a pain scale score). Lastly, we
could not objectively consider the variability of experience
and therapeutic planning associated with the three
interventional radiologists or use exclusively the internally
cooled electrode system for RF ablation. 
In conclusion, our results suggest that the percutaneous
RF ablation of HCC abutting the diaphragm is safe without
major complications. However, it is less effective with
regard to the technical success and local tumor control and
it is associated with a higher rate of right shoulder pain and
transient lung injury. 
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